Seelos Therapeutics (SEEL) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Climate Change Contaminant Environment Environmental Extreme Weather Forest Materials Nature Offset Package Packaging Pandemic Raw Materials Regenerative Toxic Wind Access African American Asian Benefits Black California Consumer Privacy Act Charity Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Employee Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Incident Injuries Injury Latinx LGBTQ Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Stakeholder Supplier Supply Chain Talent Training Union Volunteer Workforce Workplace Safety Anti-corruption Assessment Assurance Attorney General Attorneys General Audit Board Oversight Bonus Bribery Chronic Class Action Lawsuit Classified Classified Board Commitment Conflict of Interest Controversy Corporate Governance Corporate Purpose Corruption ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Materiality Oversee Oversight Pledging Procurement Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Strategy Sustainability Targets Tax Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 18, 2023, the Company held the Annual Meeting. At the Annual Meeting, a total of 86,035,070 shares, or 70.6% of the Common Stock issued and outstanding as of the record date, were represented virtually or by proxy.

At the Annual Meeting, the Company’s stockholders considered four proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 12, 2023.

Set forth below is a brief description of each matter voted upon at the Annual Meeting and the voting results with respect to each matter.

Proposal No. 1: To elect two Class III directors, Margaret Dalesandro, Ph.D. and Richard W. Pascoe, nominated by the Company’s Board of Directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.

Nominee		For				Withheld				Broker Non-Votes
Margaret Dalesandro, Ph.D.			45,742,271				16,787,800				23,504,999
Richard W. Pascoe			44,352,245				18,177,826				23,504,999

Proposal No. 2: To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

For			Against				Abstentions
79,992,858				5,498,430				543,782

Proposal No. 3: To conduct an advisory (non-binding) vote on executive compensation.

For			Against				Abstentions				Broker Non-Votes
43,555,540				17,176,340				1,798,191				23,504,999

Proposal No. 4: To approve an amendment to the Company’s Articles to increase the number of authorized shares of Common Stock to a total of 480,000,000.

For			Against				Abstentions
65,747,011				19,310,768				977,291